{"aliases":[{"type":"CodeName","name":"MDV3100"},{"type":"Synonym","name":"selective androgen receptor modulator MDV3100"},{"type":"USBrandName","name":"Xtandi"},{"type":"CodeName","name":"ASP9785"},{"type":"ChemicalStructureName","name":"benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-"},{"type":"NSCNumber","name":"766085"}],"definition":{"html":"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","text":"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/enzalutamide","text":"Enzalutamide"},"nciConceptId":"C71744","nciConceptName":"Enzalutamide","termId":560774,"name":"enzalutamide","firstLetter":"e","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"enzalutamide"}